By Maddie Sorenson TheStreet downgraded shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning, MarketBeat reports. Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) opened at 63.20 on Tuesday.
All News
AUSTIN, Texas–(BUSINESS WIRE)– DJO Global, Inc., a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, is launching the new EMPOWR 3D Knee™ at this year’s Annual Meeting of the American Association of Hip and
By Casey Tingle Investigators of this study found no statistically significant difference in the rates of heterotopic ossification at 12-month follow-up between patients with ankylosing spondylitis in Taiwan who received postoperative radiation as a pr…
In previous articles, we have discussed the complex issue of assessing malpractice liability for physician judgment. Courts have traditionally been deferential to the exercise of individual physician judgment, when such judgment is asserted as a defens…
BELGRADE, Mont., Nov. 03, 2015 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical implantation of OsteoSelect PLUS Demineralized Bone Matrix (DBM) Putty,
AUDUBON, PA, November 3, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the third quarter ended September 30, 2015. Worldwide sales increased 16.3% to $137.0 million, or…
PLAINSBORO, N.J., Nov. 03, 2015 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the third quarter ending September 30, 2015. Highlights: Third quarter revenue increased 14.6% over the prior year quarter to $226.4 million and organic revenue
LEESBURG, Va., Nov. 3, 2015 (GLOBE NEWSWIRE) — K2M Group Holdings, Inc. (Nasdaq:KTWO) (the “Company” or “K2M”), a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine and minimally invasive technologies and techniques, today
LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2015, including net sales of $101.2 million, diluted loss per share from continuing operations of ($0.04) and adjusted diluted earnings per share from continuing
© 2025 MedDeviceJobs.com Powered by Careerleaf
v.4.6.1